CoChat

The Role of α-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications

Dunning, Beth Elaine, Gerich, John E. · 2007 · Endocrine Reviews

The DOI matches its Crossref record; 313 of the 323 references it cites were found in a registry or an index.

Abstract

The hyperglycemic activity of pancreatic extracts was encountered some 80 yr ago during efforts to optimize methods for the purification of insulin. The hyperglycemic substance was named "glucagon," and it was subsequently determined that glucagon is a 29-amino acid peptide synthesized and released from pancreatic alpha-cells. This article begins with a brief overview of the discovery of glucagon and the contributions that somatostatin and a sensitive and selective assay for pancreatic (vs. gut) glucagon made to understanding the physiological and pathophysiological roles of glucagon. Studies utilizing these tools to establish the function of glucagon in normal nutrient homeostasis and to document a relative glucagon excess in type 2 diabetes mellitus (T2DM) and precursors thereof are then discussed. The evidence that glucagon excess contributes to the development and maintenance of fasting hyperglycemia and that failure to suppress glucagon secretion contributes to postprandial hyperglycemia is then reviewed. Although key human studies are emphasized, salient animal studies highlighting the importance of glucagon in normal and defective glucoregulation are also described. The past eight decades of research in this area have led to development of new therapeutic approaches to treating T2DM that have been shown to, or are expected to, improve glycemic control in patients with T2DM in part by improving alpha-cell function or by blocking glucagon action. Accordingly, this review ends with a discussion of the status and therapeutic potential of glucagon receptor antagonists, alpha-cell selective somatostatin agonists, glucagon-like peptide-1 agonists, and dipeptidyl peptidase-IV inhibitors. Our overall conclusions are that there is considerable evidence that relative hyperglucagonemia contributes to fasting and postprandial hyperglycemia in patients with T2DM, and there are several new and emerging pharmacotherapies that may improve glycemic control in part by ameliorating the hyperglycemic effects of this relative glucagon excess.

Overview

Integrity signals

Registry

Crossref · 10.1210/er.2006-0026

Cites

313 of 313 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Items 201–313 of 313

Research works printed but not linked: 9

  1. 2005, Sandostatin LAR depot (octreotide acetate for injectable suspension).
  2. 2005, Byetta (exenatide injection)[prescribing information].
  3. Pratley, 2005, Dipeptidyl peptidase-4 inhibition in type 2 diabetes mellitus., Sci Med, 10, 13
  4. Villhauer, 2001, DPP-IV inhibition and therapeutic potential., Annu Rep Med Chem, 36, 191
  5. Balas, J Clin Endocrinol Metab
  6. Dejager, Horm Metab Res
  7. Bosi, Diabetes Care
  8. Rosenstock, Diabetes Obes Metab
  9. Garber, Diabetes Obes Metab

Cited by

See all 421

Metadata

Authors
Dunning, B. E., & Gerich, J. E.
Affiliations
  • PharmaWrite, Princeton, New Jersey 08540
  • University of Rochester Medicine (US)
Corresponding author
Gerich, John E.
Venue
Endocrine Reviews
Published
2007-04-04
Volume
28
Issue
3
Pages
253-283
ISSN
  • 0163-769X (ISSN-L)
  • 1945-7189
OpenAlex
W2088987697
Cited by
369
References
323
Citations by year
2026: 6 · 2025: 7 · 2024: 16 · 2023: 17 · 2022: 14 · 2021: 20 · 2020: 15 · 2019: 21 · 2018: 17 · 2017: 24 · 2016: 25 · 2015: 23 · 2014: 24 · 2013: 27 · 2012: 27
FWCI
2.77
Type
journal article
Language
en
Open access
closed
Locations
  • Endocrine Reviews (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Bristol-Myers Squibb
  • Pfizer
  • GlaxoSmithKline
  • Sanofi
  • University of Rochester
  • Kowa Company
  • Eisai
  • Novo Nordisk
  • Medical Center, University of Rochester
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
glucagon, alpha cells, type 2 diabetes, fasting hyperglycemia, postprandial hyperglycemia, hyperglucagonemia, glucagon receptor antagonists, somatostatin, GLP-1 receptor agonists, DPP-4 inhibitors, glucagon secretion, glycemic control, glucoregulation
MeSH terms
Animals, Diabetes Mellitus, Type 2, Fasting, Glucagon, Humans, Hyperglycemia, Receptors, Glucagon, Postprandial Period, Glucagon-Secreting Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.